首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >ANTIMUTAGENIC POTENTIAL OF LIV52 BY AMES SALMONELLA/MAMMALIAN: MICROSOME MUTAGENICITY ASSAY
【24h】

ANTIMUTAGENIC POTENTIAL OF LIV52 BY AMES SALMONELLA/MAMMALIAN: MICROSOME MUTAGENICITY ASSAY

机译:AMES SALMONELLA /哺乳动物对LIV52的潜在抗药性:微观诱变分析

获取原文
           

摘要

Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This study was undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test. Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52. Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study was carried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation. Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52 showed 48.4% and 47.2% of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activation in TA1538, Liv52 showed 99.8%, 99.8%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smoke condensate, respectively. In TA100 maximum of 100%, 100%, 97.7%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced by all the above said mutagens were observed in preincubation modification method. Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and without metabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenic in nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factors in Liv52 which act by different mechanisms are strongly indicated. Keywords: Liv52 syrup, Salmonella mutagenicity test, Ames test, Desmutagens.
机译:目的:据报道,Liv52是一种无毒的草药制剂,具有肝毒性和广泛的肝病的临床活性。这项研究旨在通过沙门氏菌诱变性测试评估Liv52的诱变/抗诱变潜力。方法:使用Ames沙门氏菌/哺乳动物-微粒体诱变试验评估Liv52的诱变或抗诱变潜力。鼠伤寒沙门氏菌测试仪菌株TA1537,TA1538,TA100和TA102用于致突变性测试。在测试菌株TA1538和TA100中针对具有和不具有代谢激活的各种标准诱变剂进行了抗诱变性研究。结果:Liv52在有和没有代谢激活的情况下均未显示出任何诱变潜力,而在TA1538和TA 100测试菌株中,Liv52分别显示出48.4%和47.2%的4-硝基-O-苯二胺诱导的对他+回复子的抑制作用。随着TA1538中的代谢活化,Liv52对2-氨基芴,2-蒽氨酸和香烟烟雾冷凝物分别诱导的his +还原蛋白表现出99.8%,99.8%和100%的抑制作用。在TA100中,分别观察到2-氨基芴,2-蒽氨酸,苯并(a)and和香烟烟雾冷凝物分别诱导的his +还原酶的100%,100%,97.7%和100%抑制。在预温育修饰方法中观察到由上述所有诱变剂诱导的对his +回复子的抑制作用显着增强。结论:在沙门氏菌测定中发现Liv52是非致突变性的,而在有或没有代谢激活的情况下均表现出抗诱变的潜力。 Liv52在预温育下增强的抗诱变活性表明抗诱变因子在本质上可能是去诱变的。 Liv52发挥抗诱变潜力的确切机制尚不清楚。强烈表明了Liv52中具有通过不同机制起作用的多种抗诱变因子的可能性。关键字:Liv52糖浆,沙门氏菌致突变性测试,Ames测试,去链霉菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号